{
    "question": "What is the mechanism of action of memantine in treating Alzheimer's Disease?",
    "category": "Treatment",
    "essential_info": [
        "Blocks NMDA (N-methyl-D-aspartate) receptors.",
        "Prevents excitotoxicity caused by excessive glutamate.",
        "Memantine regulates glutamate activity without blocking normal nuerotransmission",
        "Used to treat moderate-to-severe Alzheimer's disease."
    ],
    "responses": [
        {
            "model": "gemma2-9b-it",
            "general_llm": "Memantine is a medication used to treat moderate to severe Alzheimer's disease.  \n\nIts primary mechanism of action involves modulating the activity of **N-methyl-D-aspartate (NMDA) receptors** in the brain.  \n\nHere's a breakdown:\n\n* **NMDA Receptors:** These are specialized receptors in neurons that play a crucial role in learning, memory, and communication between brain cells.  In Alzheimer's disease, overactivation of NMDA receptors contributes to the damage and death of brain cells.\n\n* **Memantine's Role:** Memantine acts as an **NMDA receptor antagonist**, meaning it blocks or reduces their activity. It does this in a **use-dependent manner**. This means it mainly blocks excessive stimulation of NMDA receptors, allowing normal, healthy activity to continue.\n\nEssentially, memantine helps to protect brain cells from the damaging effects of excessive glutamate, a neurotransmitter that binds to NMDA receptors. By controlling NMDA receptor activity, memantine aims to slow down the progression of cognitive decline in Alzheimer's disease.\n\n\nWhile memantine can offer some benefits for individuals with moderate to severe Alzheimer's, it's important to note that it does not cure the disease nor completely stop its progression. It is typically used in conjunction with other treatments and management strategies.\n\n",
            "perfect_rag": "Memantine acts as an antagonist for the N-methyl-D-aspartate (NMDA) receptor subtype of the glutamate receptor. This blockage prevents the overactivation of glutamate receptors, counteracting the excessively active glutaminergic system believed to contribute to the neurotoxicity observed in Alzheimer's disease.  \n",
            "rag_pipeline": "Memantine acts as an uncompetitive NMDA receptor antagonist.  At therapeutic doses, it can promote synaptic plasticity and protect against the excitotoxic destruction of cholinergic neurons.  The drug may also offer disease-modifying effects by inhibiting weak NMDA receptor-dependent excitotoxicity, a process believed to contribute to neuronal loss in Alzheimer's.  Additionally,  memantine may protect against beta-amyloid toxicity and possibly inhibit Abeta production. \n"
        },
        {
            "model": "llama-3.1-8b-instant",
            "general_llm": "Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the treatment of Alzheimer's disease. The primary mechanism of action for memantine in treating Alzheimer's disease involves the modulation of glutamate neurotransmission.\n\nIn the brain, excessive release of glutamate is associated with neurodegeneration. This is because excess glutamate can lead to overactivation of NMDA receptors, which can cause calcium influx into neurons. Elevated intracellular calcium levels can ultimately lead to neuronal excitotoxicity, oxidative stress, and cell death.\n\nMemantine acts by selectively blocking NMDA receptors at high glutamate concentrations, thereby reducing the influx of calcium into neurons. This blockade prevents the excitotoxic effects of excess glutamate on neurons, which in turn can help to preserve neuronal integrity.\n\nBy reducing the excitotoxic effects of glutamate, memantine may help to slow down the progression of symptoms in Alzheimer's disease, such as memory loss, cognitive decline, and behavioral changes. However, memantine does not affect the underlying pathophysiology of the disease; rather, it provides symptomatic relief by mitigating the effects of excessive glutamate.\n\nIt's worth noting that memantine's effectiveness may be greatest in patients with more advanced Alzheimer's disease, as the excitotoxic effects of glutamate are thought to play a more significant role in the disease's progression in its later stages.",
            "perfect_rag": "Memantine's mechanism of action in treating Alzheimer's disease involves blocking the N-methyl-D-aspartate (NMDA) receptor subtype of glutamate receptors. Specifically, it is an uncompetitive, low-affinity, open-channel blocker that selectively enters the receptor-associated ion channel during its open state, preventing the disruption of normal synaptic transmission. This blocking action safeguards against further damage caused by excitotoxicity-induced neuronal cell death, which is believed to contribute to the neurotoxicity observed in Alzheimer's disease. By counteracting an excessively active glutaminergic system, memantine facilitates normal activity and provides neuroprotection.",
            "rag_pipeline": "The mechanism of action of memantine in treating Alzheimer's disease involves its interaction with NMDA receptors. Memantine acts as an uncompetitive (channel blocking) antagonist of NMDA receptors at therapeutic concentrations. This blockade could theoretically inhibit the \"weak\" NMDA receptor-dependent excitotoxicity, which is believed to contribute to the progressive neuronal loss characteristic of Alzheimer's disease. Additionally, memantine can promote synaptic plasticity and enhance memory, as well as protect against the excitotoxic destruction of cholinergic neurons. At clinically relevant concentrations, memantine may also abrogate beta-amyloid toxicity and possibly inhibit its production."
        },
        {
            "model": "llama-3.3-70b-versatile",
            "general_llm": "Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist that is used in the treatment of moderate to severe Alzheimer's disease. The mechanism of action of memantine involves blocking the action of glutamate, a neurotransmitter, at NMDA receptors in the brain.\n\nIn Alzheimer's disease, there is an excessive release of glutamate, which can lead to overactivation of NMDA receptors. This overactivation can cause an influx of calcium ions into neurons, leading to neuronal damage and death through a process called excitotoxicity. Excitotoxicity is thought to contribute to the progression of Alzheimer's disease.\n\nMemantine works by binding to NMDA receptors and blocking the flow of calcium ions into the neuron. This blockade reduces the excitatory effects of glutamate and decreases the amount of calcium ions that enter the neuron, thereby reducing the risk of excitotoxicity. By blocking NMDA receptors, memantine helps to normalize the glutamatergic neurotransmission and prevents further neuronal damage.\n\nThe effects of memantine on NMDA receptors are thought to be voltage-dependent, meaning that the drug preferentially blocks NMDA receptors that are overactive, while sparing those that are functioning normally. This selective blockade allows memantine to target the pathological overactivation of NMDA receptors, while minimizing its impact on normal neurotransmission.\n\nThe clinical benefits of memantine in Alzheimer's disease are thought to result from its ability to slow down the progression of neuronal damage and death, thereby preserving cognitive function. Memantine has been shown to improve cognitive function, slow down cognitive decline, and reduce the severity of symptoms in patients with moderate to severe Alzheimer's disease. However, the exact relationship between the blockade of NMDA receptors and the clinical benefits of memantine is not fully understood and may involve other mechanisms, such as modulation of other neurotransmitter systems.\n\nIt is worth noting that memantine is often used in combination with cholinesterase inhibitors, such as donepezil, to treat Alzheimer's disease. The combination of these two types of drugs may provide a synergistic effect, as cholinesterase inhibitors can help to increase the levels of acetylcholine in the brain, while memantine can help to reduce the excitotoxic effects of glutamate. However, the exact mechanisms by which these two types of drugs interact are not fully understood and require further research.",
            "perfect_rag": "The mechanism of action of memantine in treating Alzheimer's disease is as an uncompetitive antagonist of the NMDA subtype of glutamate receptors in the central nervous system (CNS). It blocks the extrasynaptic NMDA receptor that selectively enters the receptor-associated ion channel during its open state, preventing the disruption of normal synaptic transmission and safeguarding against further damage caused by excitotoxicity-induced neuronal cell death.\n\nMemantine counteracts the excessive stimulation of glutamate, the primary excitatory amino acid in the CNS, which is believed to contribute to the neurotoxicity observed in Alzheimer's disease. By blocking the overactivation of glutamine receptors, memantine facilitates normal activity and prevents the disruption of normal synaptic transmission.\n\nAdditionally, memantine exhibits antagonist activity at the serotonergic type 3 (5-HT3) and nicotinic acetylcholine receptors, but it has no activity at other receptors such as gamma-aminobutyric acid (GABA), benzodiazepine, dopamine, adrenergic, histamine, or glycine receptors, or for voltage-dependent calcium, sodium, or potassium channels.\n\nAs a result of its mechanism of action, memantine is commonly used in combination with acetylcholinesterase inhibitors, such as donepezil, for the treatment of Alzheimer's dementia. This combination provides a synergistic effect in treating the disease, with memantine offering neuroprotection and acetylcholinesterase inhibitors providing symptomatic relief by inhibiting cholinesterase and increasing cholinergic transmission.",
            "rag_pipeline": "Memantine acts as an uncompetitive NMDA receptor antagonist, which means it blocks NMDA receptors in a channel-blocking manner. At therapeutic concentrations, memantine interacts with NMDA receptors, and this interaction is believed to be the key target of its therapeutic activity. By blocking NMDA receptors, memantine can inhibit the excitotoxic destruction of cholinergic neurons, which may contribute to its symptomatic improvement in Alzheimer's disease treatment. Additionally, memantine's blockade of NMDA receptors may also confer disease-modifying activity by inhibiting the \"weak\" NMDA receptor-dependent excitotoxicity that plays a role in progressive neuronal loss. Furthermore, memantine's fast channel-blocking kinetics and strong voltage-dependence allow it to block channel activity induced by low, tonic levels of glutamate, which may contribute to its symptomatic improvement, while sparing synaptic responses required for normal behavioral functioning, cognition, and memory. Memantine may also abrogate beta-amyloid toxicity and possibly inhibit beta-amyloid production, although the exact mechanisms are not fully understood. Overall, memantine's unique mechanism of action as an NMDA receptor antagonist distinguishes it from other Alzheimer's disease therapies, such as cholinesterase inhibitors."
        },
        {
            "model": "meta-llama/llama-4-maverick-17b-128e-instruct",
            "general_llm": "Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist used in the treatment of moderate to severe Alzheimer's disease. Its mechanism of action is believed to involve modulation of the glutamatergic system, which is thought to play a key role in the pathophysiology of Alzheimer's disease.\n\nNormally, glutamate acts as an excitatory neurotransmitter, binding to NMDA receptors and facilitating synaptic plasticity and learning. However, excessive glutamate release can lead to overstimulation of NMDA receptors, resulting in excitotoxicity and neuronal damage. In Alzheimer's disease, it is hypothesized that abnormal glutamate release and NMDA receptor activation contribute to neurodegeneration.\n\nMemantine works by blocking NMDA receptors in a voltage-dependent manner, meaning it preferentially binds to open NMDA receptor channels. This blockade is thought to reduce excitotoxicity by:\n\n1. Inhibiting excessive calcium influx into neurons, which is a key mediator of excitotoxicity.\n2. Reducing the excitatory effects of glutamate on NMDA receptors.\n\nBy modulating NMDA receptor activity, memantine is believed to slow down the progression of neuronal damage and cognitive decline in Alzheimer's disease. It may also have a neuroprotective effect by reducing oxidative stress and inflammation.\n\nIt's worth noting that the exact mechanisms by which memantine exerts its therapeutic effects in Alzheimer's disease are not fully understood and are still being researched. However, its ability to modulate the glutamatergic system and reduce excitotoxicity is thought to be a key component of its therapeutic action.",
            "perfect_rag": "Memantine acts as an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors in the central nervous system. It blocks the extrasynaptic NMDA receptor, preventing the disruption of normal synaptic transmission and safeguarding against further damage caused by excitotoxicity-induced neuronal cell death. By counteracting the excessive stimulation of glutamate, memantine slows the neurotoxicity involved in Alzheimer's disease. Additionally, memantine exhibits antagonist activity at the serotonergic type 3 (5-HT3) and nicotinic acetylcholine receptors, but it has no activity at other receptors or channels.",
            "rag_pipeline": "Memantine's mechanism of action in treating Alzheimer's disease involves its interaction with NMDA receptors as an uncompetitive antagonist, specifically by blocking the channel. At therapeutic concentrations, memantine targets NMDA receptors. At lower, clinically relevant concentrations, it can promote synaptic plasticity and protect against excitotoxic destruction of cholinergic neurons. The blockade of NMDA receptors by memantine may also confer disease-modifying activity by inhibiting weak NMDA receptor-dependent excitotoxicity, which is hypothesized to contribute to progressive neuronal loss. Additionally, memantine has been shown to abrogate beta-amyloid toxicity and possibly inhibit its production. The unique characteristics of memantine, such as fast channel-blocking kinetics and strong voltage-dependence, allow it to block tonic NMDA receptor activity while sparing synaptic responses necessary for normal cognitive function."
        },
        {
            "model": "qwen/qwen3-32b",
            "general_llm": "<think>\nOkay, so I need to explain how memantine works in treating Alzheimer's disease. Let me start by recalling what I know about Alzheimer's and the drugs used. Alzheimer's is a neurodegenerative disease characterized by memory loss, cognitive decline, and other neurological symptoms. One of the key theories about its pathophysiology is the involvement of the glutamatergic system, specifically excessive glutamate activity leading to excitotoxicity.\n\nI remember that NMDA receptors are a type of glutamate receptor. Glutamate is a neurotransmitter that's essential for normal brain function, but too much can be toxic. Excessive activation of NMDA receptors might cause an influx of calcium ions into neurons, which can lead to cell damage or death. In Alzheimer's, this might be exacerbated by factors like amyloid-beta plaques or neurofibrillary tangles.\n\nMemantine is an NMDA receptor antagonist. So, its mechanism would be to block or modulate these receptors. But I think it's not just a complete blocker. Maybe it's a modulator that allows normal glutamate function but blocks the overstimulation. That way, it protects neurons from excitotoxicity without interfering with the necessary neuronal activity.\n\nI should also consider how memantine is different from other Alzheimer's drugs, like cholinesterase inhibitors. Cholinesterase inhibitors work by increasing acetylcholine levels, which is part of different pathways. Memantine's approach is through glutamate regulation. It's often used for moderate to severe Alzheimer's.\n\nWait, how exactly does memantine bind to the NMDA receptor? I think it's a voltage-dependent channel blocker. When the receptor is not activated, memantine doesn't block it. But when the receptor is activated by glutamate and the cell is depolarized (which makes the channel open), memantine can access the pore and block it. This prevents the excessive calcium influx during overactivation but allows normal signaling when the receptor is not overstimulated.\n\nSo, in Alzheimer's, the chronic overactivation of NMDA receptors due to high glutamate levels might be harmful. Memantine's unique mechanism helps reduce this excitotoxicity by blocking the ion channel during excessive stimulation while permitting physiological levels of glutamate to function.\n\nI should also note that while memantine doesn't stop the underlying disease process, it can help manage symptoms by protecting neurons from damage caused by excitotoxicity. It's often used in combination with cholinesterase inhibitors for a more comprehensive approach.\n\nI need to make sure I don't confuse the mechanisms of memantine with other NMDA antagonists. For example, ketamine is a NMDA antagonist too, but used for pain or depression. But memantine is specifically designed to be a low-affinity, voltage-dependent blocker to target pathological overactivation without affecting normal synaptic activity.\n\nAlso, I should mention clinical trials or evidence supporting its efficacy. However, since the user is asking about the mechanism, focusing on the pharmacological action is better. But maybe a sentence about how this mechanism helps in Alzheimer's management would be good.\n\nSo putting it all together: Memantine is an NMDA receptor antagonist that modulates glutamate activity. It blocks excessive calcium influx during prolonged or high-level activation of NMDA receptors, thereby preventing excitotoxicity in neurons. This action is crucial in conditions like Alzheimer's where such overactivation is contributing to neuronal damage. By protecting neurons from this form of damage, memantine helps in managing the symptoms of moderate to severe Alzheimer's disease, although it does not cure the disease or address all underlying pathologies.\n</think>\n\nMemantine is an NMDA (N-methyl-D-aspartate) receptor antagonist primarily used to treat moderate to severe Alzheimer's disease. Its mechanism of action is intricately linked to the regulation of glutamate, a major excitatory neurotransmitter in the central nervous system. Here's a detailed breakdown of how it works:\n\n1. **Glutamate and Excitotoxicity**: \n   - In Alzheimer's disease, excessive glutamate activity contributes to **excitotoxicity**, a process where overactivation of NMDA receptors leads to uncontrolled calcium influx into neurons. This calcium overload triggers a cascade of events, including oxidative stress, mitochondrial dysfunction, and ultimately, neuronal death.\n\n2. **Voltage-Dependent Blockade of NMDA Receptors**:\n   - Memantine selectively modulates NMDA receptors in a **low-affinity, voltage-dependent manner**. Under normal physiological conditions, it has minimal effect because the receptor channels remain closed due to magnesium block at resting membrane potentials.\n   - During pathological conditions (e.g., chronic overactivation from high glutamate levels), NMDA receptors open repeatedly, and neurons depolarize. Memantine gains access to the ion channel pore at this point, **blocking calcium influx** and preventing excitotoxic damage. This allows normal glutamatergic signaling to continue while shielding neurons from harmful, excessive stimulation.\n\n3. **Differentiation from Other Mechanisms**:\n   - Unlike cholinesterase inhibitors (e.g., donepezil), which enhance acetylcholine levels, memantine targets glutamatergic pathways. It is often used in combination with cholinesterase inhibitors to address multiple neurotransmitter dysfunctions in Alzheimer's.\n\n4. **Clinical Role**:\n   - While memantine does not halt the progression of Alzheimer's or address underlying pathologies (e.g., amyloid plaques, tau tangles), it **reduces symptomatic cognitive decline** and behavioral symptoms in moderate to severe stages. Its neuroprotective effects are believed to stem from curbing excitotoxicity associated with disease-related neuronal dysfunction.\n\n5. **Pharmacological Specificity**:\n   - Memantine\u2019s voltage-dependent mechanism ensures it primarily affects pathological receptor activation, avoiding interference with normal synaptic transmission. This specificity minimizes adverse effects compared to other NMDA antagonists (e.g., ketamine), which block receptors indiscriminately.\n\nIn summary, memantine mitigates neuronal damage in Alzheimer's by selectively inhibiting excessive NMDA receptor activity, thereby protecting neurons from excitotoxicity while preserving essential glutamatergic signaling. This makes it a cornerstone treatment for managing advanced disease stages, complementing other therapeutic strategies.",
            "perfect_rag": "<think>\nOkay, so the user is asking about the mechanism of action of memantine in treating Alzheimer's Disease. Let me look through the provided context to find the relevant information.\n\nFirst, in the section titled \"Mechanism of Action\", it mentions that memantine is an uncompetitive antagonist of the NMDA subtype of glutamate receptors in the CNS. The context explains that Alzheimer's is caused by overstimulation of glutamate, leading to excitotoxicity and neuronal degeneration. Memantine counteracts this excessive stimulation. \n\nAlso, there's a part about how the NMDAR is a voltage-gated cation channel blocked by magnesium ions when unstimulated. When stimulated, magnesium is displaced, allowing calcium influx. In Alzheimer's, this becomes chronically active, and memantine blocks the extrasynaptic NMDAR, preventing disruption of synaptic transmission and protecting against excitotoxicity-induced cell death.\n\nAnother section under \"Role of Memantine\" states that it's used in combination with cholinesterase inhibitors because its mechanism is distinct and neuroprotective. It blocks extrasynaptic NMDARs during their open state, preventing damage from excitotoxicity.\n\nAdditionally, the context notes that memantine does not affect GABA, benzodiazepine, dopamine, adrenergic, histamine, or voltage-dependent calcium channels, which means its action is specific to glutamate receptors.\n\nPutting this all together, the mechanism involves blocking NMDA receptors to prevent overactivation by glutamate, thus reducing excitotoxic damage. The key points are the uncompetitive antagonism of NMDA receptors, inhibition of calcium influx, and prevention of neuronal cell death.\n</think>\n\nMemantine treats Alzheimer's disease by acting as an antagonist of the N-methyl-D-aspartate (NMDA) receptor, a type of glutamate receptor in the central nervous system. Its mechanism of action involves **blocking excessive glutamate activity**, which is implicated in neuronal damage in Alzheimer's. Here's a detailed breakdown:\n\n1. **Glutamate Regulation**: Glutamate is the brain's primary excitatory neurotransmitter, essential for processes like learning and memory. However, excessive glutamate activation of NMDA receptors leads to **excitotoxicity**, causing calcium influx into neurons and subsequent cell death. Memantine **inhibits this overactivation** by selectively binding to NMDA receptors in an uncompetitive, low-affinity manner.\n\n2. **NMDA Receptor Blockade**: Memantine blocks **extrasynaptic NMDA receptors** (those outside synaptic junctions) when they are in an open state, preventing pathologic calcium influx while sparing normal synaptic transmission. This action safeguards against neurotoxicity without disrupting essential neurological functions.\n\n3. **Protection Against Neurodegeneration**: By countering chronic overstimulation of NMDA receptors, memantine reduces excitotoxic damage to neurons, which is a key contributor to cognitive decline in Alzheimer's. It does not interfere with physiological glutamatergic processes but focuses on **attenuating pathological activity**.\n\n4. **Distinct From Cholinesterase Inhibitors**: Unlike cholinesterase inhibitors (e.g., donepezil), which enhance acetylcholine signaling, memantine offers **neuroprotection** by targeting glutamate pathways. This dual-action approach (when used in combination with cholinesterase inhibitors) provides both symptomatic relief and disease-modifying effects.\n\nMemantine is approved for moderate-to-severe Alzheimer's disease and is often combined with acetylcholinesterase inhibitors to leverage complementary mechanisms, enhancing functional outcomes while minimizing neurotoxic damage.",
            "rag_pipeline": "<think>\nOkay, let's see. The user is asking about the mechanism of action of memantine in treating Alzheimer's Disease. I need to base my answer solely on the provided context.\n\nFirst, I remember the context mentions that memantine is an uncompetitive, channel-blocking NMDA receptor antagonist. That's a key point. So it blocks NMDA receptors but in a specific way. Unlike cholinesterase inhibitors, which are different drugs used for AD, memantine works through NMDA receptors. \n\nThe context says that at therapeutic concentrations, NMDA receptors are the main target. But high concentrations can inhibit synaptic plasticity, which is important for learning and memory. However, at lower concentrations, it might actually promote synaptic plasticity and help with memory in animal models. Interesting, so there's a concentration-dependent effect here. \n\nThen there's the part about excitotoxicity. Memantine blocks NMDA receptors, which might prevent excitotoxic destruction of cholinergic neurons. The hypothesis here is that excitotoxicity due to weak NMDA receptor activation contributes to neuronal loss in AD. By blocking these receptors, especially under low glutamate conditions, memantine could be protecting neurons from this weak excitotoxicity. \n\nAlso mentioned are effects on beta-amyloid toxicity. Recent studies suggest memantine can abrogate beta-amyloid toxicity and possibly inhibit its production. That adds another layer to its mechanism beyond NMDA receptor blockade. \n\nThere's also something about the tolerability compared to other NMDA antagonists. The context lists factors like fast channel-blocking kinetics, strong voltage-dependence, and reduced trapping. These features allow memantine to block low tonic glutamate activity without interfering with normal synaptic activity, which is important for maintaining cognitive functions. \n\nPutting this all together: The main mechanism involves NMDA receptor antagonism, preventing excitotoxicity, and possibly affecting beta-amyloid pathways. The drug's unique properties at different concentrations and its ability to spare normal synaptic function during therapeutic use are also critical points.\n</think>\n\nMemantine exerts its therapeutic effects in Alzheimer's disease (AD) through several interconnected mechanisms, primarily centered on modulating NMDA (N-methyl-D-aspartate) receptors and mitigating excitotoxicity. As an uncompetitive, channel-blocking NMDA receptor antagonist, memantine selectively inhibits excessive glutamate activity, which is implicated in neurodegeneration in AD. At therapeutic concentrations, it preferentially targets low levels of tonic glutamate stimulation, where overactivation can lead to excitotoxic neuronal damage. This action is thought to protect cholinergic neurons from excitotoxicity, a process hypothesized to underlie progressive neuronal loss in AD. \n\nMemantine's distinct pharmacological profile allows it to block pathological glutamate activity while sparing synaptic plasticity required for normal cognitive function. At lower doses, it may even enhance synaptic plasticity and improve memory in preclinical models of AD, contrasting with its potential to impair synaptic plasticity at higher concentrations. Additionally, memantine may counteract beta-amyloid (A\u03b2) toxicity and potentially reduce A\u03b2 production, adding another neuroprotective pathway. Its tolerability compared to other NMDA antagonists stems from features like rapid channel-block kinetics, voltage-dependent binding, and reduced trapping, enabling therapeutic blockade of harmful excitotoxic signals without disrupting physiological synaptic transmission. These mechanisms collectively contribute to symptomatic relief and possibly disease-modifying effects in AD."
        }
    ]
}